Tubulointerstitial damage and progression of renal failure.
The present work reviews the mechanisms and close association between glomerular and tubular damage and its relationship to renal functional impairment. In addition, we present an overview of the pathways involved in the progression of tubulointerstitial fibrosis and a brief summary of the treatments used to retard the progression to end-stage renal failure.
Rodríguez-Iturbe
Bernardo
B
Hospital Universitario and Universidad del Zulia, Maracaibo, Venezuela. bernardori@telcel.net.ve
Johnson
Richard J
RJ
Herrera-Acosta
Jaime
J
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D018450:Disease Progression; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007668:Kidney / Q000098:blood supply / Q000503:physiopathology*; D007676:Kidney Failure, Chronic / Q000503:physiopathology / Q000517:prevention & control; D018919:Neovascularization, Physiologic / Q000187:drug effects; D009395:Nephritis, Interstitial / Q000188:drug therapy / Q000503:physiopathology*; D051437:Renal Insufficiency / Q000188:drug therapy / Q000503:physiopathology*
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D007166:Immunosuppressive Agents; D004921:Erythropoietin